Summary
=======

To test the hypothesis that fibrotic burden in remote myocardium quantified by CMR during early period of infarct healing is a strong determinant of the cardiac remodeling outcome.

Background
==========

After acute myocardial infarction (AMI), co-existing myocardial stunning, ischemia, and architectural alteration may yield variable patterns of ventricular remodeling with potential long-term prognostic implications. We hypothesize that CMR quantification of fibrotic content, based on R1 (1/T1) assessment, in non-infarct myocardium early after infarction and during the infarct healing phases may provide novel prediction of the final infarct size and alteration of ventricular functions during infarct healing.

Methods
=======

We quantified infarct size by late gadolinium enhancement (LGE), mean segmental fibrotic index (FI~MeanSeg~) and total LV fibrotic burden (FI~Total~), ventricular function and sizes during subacute (2-4 weeks) and chronic stages (6 months) of healing in 62 AMI patients (45 men, mean LVEF 55±8%). Infarct-healing period was defined as the time between the subacute and the chronic stages. For the purpose of quantifying FI~MeanSeg~ and FI~Total~, we serially quantified the ratio of myocardial to blood pool R1 changes (from before, and up to 30 minutes after contrast injection) to measure the expansion of the extracellular matrix as a marker of fibrosis. Three parallel short-axis slices were acquired for fibrotic quantification using a cine-IR sequence and slice-matched LGE imaging. Myocardial segments with any LGE were excluded from quantification of fibrotic indices. Serum hematocrit was used to estimate the plasma R1 from the measured blood R1.

Results
=======

From subacute to chronic stage, FI~MeanSeg~ in remote myocardium increased significantly (from 0.32±0.05 to 0.35±0.07, P=0.008). Severity of increased FI~MeanSeg~ during the infarct-healing period was correlated to the severity in worsening of LVEF (r=-0.27, P=0.03), trend worsening of LVESV (r=0.24, P=0.07), and significant worsening of RVESV (r=0.34, P=0.009). Linear regression demonstrated that FI~MeanSeg~ was one of the strongest predictors of final infarct mass (in grams) at the chronic stage. Specifically, both FI~MeanSeg~ at the subacute stage and its change during the infarct-healing period, demonstrated strong and independent association with the extent of the final infarct mass at the chronic stage, incremental to infarct mass measured at the subacute stage (P=0.004 and P=0.02, respectively, for improved model F-value).

Conclusions
===========

Quantification of non-infarcted fibrotic burden during subacute stage and its change during infarct-healing provides strong prediction of the severity of the LV and RV post-MI remodeling and of final infarct size at 6 months.
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